EARS Stock News: Auris Medical Holding Ltd nearly quintuples on promising coronavirus treatment

NASDAQ: EARS has leaped by 370% on Tuesday following promising news.
Auris Medical Holding reported that its nasal spray could protect against coronavirus.
A downside correction may make it a buying opportunity.

Yohay Elam FXStreet

Investors will likely be all-ears to hear about a coronavirus treatment which is not invasive – Auris Medical Holding Ltd (NASDAQ: EARS) has jumped from $1.11 to close at $5.23 after hitting a high of $6.60 at one point – nearly a sixfold leap – before closing at "only" a 370% gain, nearly quintupling.

With all the buzz about COVID-19 vaccines, markets seem to have forgotten about treatments – and especially prevention. Auris' AM-301 solution is a nasal spray that may protect against pathogens and also allergens that travel via aerosols.

The Zug, Switzerland-based firm has shared results from an in-vitro test, a stage before testing it on animals or humans. Nevertheless, the tests have shown a reduction of the virus by up to 90%, similar to the efficacy rates of the Pfizer/BioNTech and Moderna vaccines.

While the UK gave its green light to Pfizer's jabs, it may take some time until they can be distributed and administered. In the meantime, cheap means of prevention can help in stopping the spread of the disease that grips the world.

EARS stock forecast

NASDAQ: EARS is falling by around 20% in Wednesday's premarket trading, a much-needed correction after the whopping surge. For traders, the question is – will Auris stocks resume their gains? Even if covid disappears by the end of 2021, the company is now on the radar of investors. Allergies are unlikely to go away anytime soon, and nor are other issues that the company addresses.

The small pharma firm – worth a minuscule $37 million – in developing a drug called Sonsuvi which is used to treat sudden deafness. Sonsuvi has already reached Phase 3 trials and may be ready for markets next year.

All in all, there is room for some upside after the recent correction.

Premium

You have reached your limit of 3 free articles for this month.

Start your subscription and get access to all our original articles.

Subscribe to Premium Sign In

Author

Yohay Elam

FXStreet

Yohay is in Forex since 2008 when he founded Forex Crunch, a blog crafted in his free time that turned into a fully-fledged currency website later sold to Finixio.

GBP/USD surges to multi-day peaks past 1.3250

GBP/USD leaves behind Friday’s small pullback and advances past 1.3250 level, or five-day highs, on Monday. Cable’s upside follows extra losses in the Greenback, while traders continue to assess the geopolitical front and upcoming key events.

EUR/USD picks up extra pace north of 1.1400

EUR/USD extends its recovery past 1.1400 the figure as the NA session draws to a close on Monday. Indeed, the pair advances for the third straight day amid the persistent offered bias in the US Dollar. Meanwhile, market participants keep gearing up for the ECB Forum in Sintra and the release of critical US labour market data.

Gold struggles to attract investors

Gold remains under marked selling pressure, holding on just above the key $4,000 mark per troy ounce at the beginning of the week. The precious metal reverses two daily advances in a row as renewed effervescence in the Middle East revive inflation concerns and bolster Fed rate hike expectations.

Strategy unveils plan allowing Bitcoin sales to fund stock buybacks, dividends and reserves

Strategy (MSTR) has unveiled a Digital Credit Framework to strengthen the company’s financial standing. Under the new framework, the world’s largest corporate holder of Bitcoin (BTC) will pivot from its previous accumulation strategy, opting to sell BTC in order to boost liquidity, fund dividend payments, execute stock buybacks, and strengthen cash reserves.

Just like Fed, is BoJ’s independence under threat?

When talking about central bank independence, most of the focus has been on Donald Trump’s pressure on the Federal Reserve. But a similar story, a quieter one for now, seems to be happening on the other side of the Pacific: Japan’s government may be testing the Bank of Japan’s independence.

Kevin Warsh isn't expected to say much in Sintra: That's exactly why markets will listen

Financial markets could find an important catalyst in the enchanting, fairytale-like landscape of Sintra this week. The ECB Forum will, as it does every year, gather the crème de la crème of central banks. The new boss at the Fed, who has clearly said that the Fed should stop explaining everything, will need to talk – and traders should listen.